This recombinant FH (GEM-103) was evaluated in phase I (NCT04246866) and II (NCT04643886) clinical trials in AMD patients (49) but failed to achieve its clinical end points and the developmental program was terminated (50). This evidence concerns the gene FH and age-related macular degeneration.